Polycystic Ovary Syndrome Renamed PMOS to Reflect Hormonal and Metabolic Nature
Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change addresses the fact that many women with the condition do not have ovarian cysts, despite the previous name's suggestion. The new name aims to better represent its understanding as a hormonal and metabolic disorder, impacting diagnosis, treatment, and long-term health.
Polycystic Ovary Syndrome (PCOS), a condition previously named for its association with ovarian cysts, has undergone a significant name change. It is now officially known as Polyendocrine Metabolic Ovarian Syndrome (PMOS).
This renaming reflects an updated understanding of the disorder, as many women diagnosed with the condition do not actually present with ovarian cysts. The original name was often considered misleading due to this discrepancy.
The new designation, PMOS, underscores that the condition is increasingly recognized as a complex hormonal and metabolic disorder. This reclassification aims to provide a more accurate and comprehensive view of the syndrome's underlying mechanisms.
Experts have discussed how this name change will impact the diagnosis, treatment approaches, and overall long-term health management for women affected by the condition.
According to Channel News Asia, this development signifies a shift in medical understanding and communication regarding the disorder.
